Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effects—including anti-inflammatory, antioxidant, and neuroprotective properties—that position them as transformative candidates for ocular therapeutics. The gene discussed is GLP1R; the disease is Obesity.